Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Avid Bioservices Inc CDMO

Healthcare Biotechnology
Avid Bioservices, Inc. is a contract development and manufacturing organization (CDMO). The Company provides a range of services from process development to Current Good Manufacturing Practices (CGMP) clinical and commercial manufacturing of biologics for the biotechnology and biopharmaceutical industries. It operates in a single segment, which is contract manufacturing and development services... see more

Recent & Breaking News (NDAQ:CDMO)

SHAREHOLDER ALERT: Avid Bioservices Investigated by Block & Leviton For Potential Securities Law Violations; Investors Who Have Lost Money Are Encouraged to Contact the Firm

Newsfile March 8, 2024

Avid Bioservices, Inc. (CDMO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings

Accesswire March 8, 2024

Avid Bioservices, Inc. (CDMO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings

Accesswire March 7, 2024

CDMO LOSS ALERT: ROSEN, A LEADING LAW FIRM, Encourages Avid Bioservices, Inc. Investors to Inquire About Securities Class Action Investigation - CDMO

Business Wire March 7, 2024

Avid Bioservices Announces Pricing of Private Placement of Convertible Notes

GlobeNewswire March 6, 2024

Avid Bioservices Announces Proposed Private Placement of Convertible Notes

GlobeNewswire March 6, 2024

Avid Bioservices Announces Certain Preliminary Financial Results for Third Quarter Ended January 31, 2024

GlobeNewswire March 6, 2024

Avid Bioservices Reports Financial Results for Second Quarter Ended October 31, 2023

GlobeNewswire December 7, 2023

Uber Technologies, Jabil and Builders FirstSource Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600

PR Newswire December 1, 2023

Avid Bioservices to Report Financial Results for Second Quarter of Fiscal Year 2024 After Market Close on December 7, 2023

GlobeNewswire November 30, 2023

Avid Bioservices Partners With California Institute for Regenerative Medicine (CIRM) to Provide CDMO Services for Cell and Gene Therapy (CGT) Programs

GlobeNewswire November 8, 2023

Avid Bioservices Completes Construction of New, World-Class Cell and Gene Therapy Development and Manufacturing Facility

GlobeNewswire October 17, 2023

Avid Bioservices to Participate in RBC Capital Markets Virtual CDMO Conference

GlobeNewswire September 26, 2023

Avid Bioservices Reports Financial Results for First Quarter Ended July 31, 2023

GlobeNewswire September 7, 2023

Avid Bioservices to Report Financial Results for First Quarter of Fiscal Year 2024 After Market Close on September 7, 2023

GlobeNewswire August 31, 2023

Avid Bioservices Reports Financial Results for Fourth Quarter and Fiscal Year Ended April 30, 2023

GlobeNewswire June 21, 2023

Avid Bioservices to Report Financial Results for Quarter and Fiscal Year Ended April 30, 2023 After Market Close on June 21, 2023

GlobeNewswire June 14, 2023

Avid Bioservices to Participate in RBC Capital Markets Global Healthcare Conference

GlobeNewswire May 10, 2023

Avid Bioservices Unveils Completed Mammalian Cell Facilities Expansion Providing Significantly Increased Capacity for Existing and Future Customers

GlobeNewswire April 4, 2023

Avid Bioservices Reports Financial Results for Third Quarter Ended January 31, 2023, and Recent Developments

GlobeNewswire March 13, 2023